Human LILRA5/CD85f/ILT11 Protein


Cat. No. LIL-HM4A5

Description Recombinant Human LILRA5/CD85f/ILT11 Protein is expressed from HEK293 with His tag and Avi tag at the C-Source Terminus. It contains Gly42-Arg268. Accession A6NI73-1 The protein has a predicted MW of 28.2 kDa. Due to glycosylation, the protein migrates to 38-50 kDa based on Molecular Weight Bis-Tris PAGE result. Endotoxin Less than 1EU per µg by the LAL method. > 95% as determined by Bis-Tris PAGE Purity > 95% as determined by HPLC Formulation and Storage Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before Formulation lyophilization. Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Reconstitution Dissolve the lyophilized protein in distilled water. -20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3 months after reconstitution. Recommend Storage to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. Background The leukocyte immunoglobulin-like receptors (LILR) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIRs). Human LILRA5, also known as ILT11, LIR-9, and CD85f, consists of a 227 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 10 aa cytoplasmic tail. LILRA5 may play a role in triggering

innate immune responses. Does not seem to play a role for any class I MHC antigen recognition.

Assay Data






Human LILRA5 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

KAGJUS

SEC-HPLC



The purity of Human LILRA5 is greater than 95% as determined by SEC-HPLC.